Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 35Sarcoma 7Genitourinary 2Other solid neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1Gastrointestinal 1Dermatologic 1

Conditions

Melanoma 136Lymphoma, T-Cell, Cutaneous 45Lymphoma, Non-Hodgkin 37Lymphoma, Follicular 36Precursor Cell Lymphoblastic Leukemia-Lymphoma 35Lymphoma, Large B-Cell, Diffuse 35Lymphoma, Large-Cell, Immunoblastic 34Leukemia, Lymphocytic, Chronic, B-Cell 34Lymphoma, Mantle-Cell 33Lymphoma, B-Cell, Marginal Zone 33Burkitt Lymphoma 33Lymphoma 32Leukemia, Myeloid, Acute 32Hodgkin Disease 31Mycosis Fungoides 30Sezary Syndrome 29Multiple Myeloma 28Leukemia, Myeloid, Accelerated Phase 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 24Neoplasm Metastasis 24Leukemia, Myeloid, Chronic-Phase 24Leukemia 23Myelodysplastic Syndromes 22Lymphoma, Large-Cell, Anaplastic 22Congenital Abnormalities 22Blast Crisis 22Skin Neoplasms 20Immunoblastic Lymphadenopathy 20Myeloproliferative Disorders 19Recurrence 18

Interventions

sonidegib 2Etoposide 2Carboplatin 2tipifarnib 1merphos 1entinostat 1carboxyamido-triazole 1bempegaldesleukin 1Vincristine 1Thrombopoietin 1Thalidomide 1Paclitaxel 1Oxaliplatin 1Nivolumab 1NVP-LEQ506 1Methotrexate 1Mental Status and Dementia Tests 1LY2940680 1Irinotecan 1Immunologic Techniques 1Ifosfamide 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Fentanyl 1Docetaxel 1Cyclophosphamide 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Medulloblastoma × Cyclophosphamide × Dermatologic × Clear all
NCT02017964 2023-01-09

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma

Children's Oncology Group

Phase 2 Completed
26 enrolled 14 charts
CNSDermatologic

Basal Cell Nevus Syndrome, Medulloblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡